Graded
Ministerstwo zdrowia USA opublikowało projekt zasad, według którego nie będzie ścigać aptek przygotowujących BPC-157 na receptę dla konkretnej osoby, dopóki FDA nie zdecyduje w przepisach. To nadal nie jest dopuszczony lek.
EN

PT-141

Wróć do opisu substancji

Prace naukowe

BadaniaRodzaj badaniaRok
Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options.J Minim Invasive GynecolAnaliza zbiorcza2026
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women.J Sex ResAnaliza zbiorcza2021
Female Sexual Dysfunction and the Placebo Effect: A Meta-analysis.Obstet GynecolAnaliza zbiorcza2018
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.J Womens Health (Larchmt)Z losowaniem grup2022
Safety Profile of Bremelanotide Across the Clinical Development Program.J Womens Health (Larchmt)Z losowaniem grup2022
The Patient Experience of Premenopausal Women Treated with Bremelanotide for Hypoactive Sexual Desire Disorder: RECONNECT Exit Study Results.J Womens Health (Larchmt)Z losowaniem grup2021
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.Obstet GynecolZ losowaniem grup2019
Responder Analyses from a Phase 2b Dose-Ranging Study of Bremelanotide.J Sex MedZ losowaniem grup2019
Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide.J HypertensZ losowaniem grup2017
Phase I Randomized Placebo-controlled, Double-blind Study of the Safety and Tolerability of Bremelanotide Coadministered With Ethanol in Healthy Male and Female Participants.Clin TherZ losowaniem grup2017
Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial.Womens Health (Lond)Z losowaniem grup2016
RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder: a double-blind placebo-controlled, fixed dose, randomized study.J Sex MedWycofaneZ losowaniem grup2008
Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study.J UrolZ losowaniem grup2008
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist.J Sex MedZ losowaniem grup2006
Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.UrologyZ losowaniem grup2005
Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.Int J Impot ResZ losowaniem grup2004
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction.Int J Impot ResZ losowaniem grup2004
Gateways to clinical trials.Methods Find Exp Clin PharmacolBez losowania grup2004
PT-141: a melanocortin agonist for the treatment of sexual dysfunction.Ann N Y Acad SciBez losowania grup2003
Gap in Sexual Dysfunction Management Between Male and Female Patients Seen in Primary Care: An Observational Study.J Gen Intern MedObserwacja grupy2025
First-time orgasm in a young man with lifelong anorgasmia after flibanserin use: a case report.Sex MedOpisy przypadków2023
Melanotan II injection resulting in systemic toxicity and rhabdomyolysis.Clin Toxicol (Phila)Opisy przypadków2012
Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review.Sex Med RevPrzegląd badań2026
Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer.J Minim Invasive GynecolPrzegląd badań2026
Clinical trial evidence on emerging pharmacological therapies for hypoactive sexual desire disorder in women: a systematic review and analysis of completed studies registered on ClinicalTrials.gov.Front Med (Lausanne)Przegląd badań2026
FDA-Approved Drugs Containing D-Amino Acids: A Historical and Developmental Perspective.Drug Dev ResPrzegląd badań2026
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.Int J Mol SciPrzegląd badań2026
Therapeutic peptides in gerontology: mechanisms and applications for healthy aging.Front AgingPrzegląd badań2026
Quantification of "Mercy Sex" in Heterosexual Women.J Sex Marital TherPrzegląd badań2026
Practical considerations and emerging approaches for the management of vasomotor and sexual symptoms in breast cancer patients on endocrine therapies.Expert Rev Clin PharmacolPrzegląd badań2025
Polymorphism of Melanocortin Receptor Genes-Association with Inflammatory Traits and Diseases.DiseasesPrzegląd badań2025
2024 SOGC, 2024 NCCN, 2022 ESO-ESMO, and 2018 ASCO: a comparison of female cancer survivorship guidelines for the management of sexual health concerns.Support Care CancerPrzegląd badań2025
Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions.Expert Opin PharmacotherPrzegląd badań2025
Novel Pharmacologic Treatments of Female Sexual Dysfunction.Clin Obstet GynecolPrzegląd badań2025
Pharmacotherapy of Hypoactive Sexual Desire Disorder in Premenopausal Women.Ann PharmacotherPrzegląd badań2025
Understanding the Interplay Between Premenstrual Dysphoric Disorder (PMDD) and Female Sexual Dysfunction (FSD).CureusPrzegląd badań2024
Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.J Sex ResPrzegląd badań2024
A Comprehensive Review of Novel FDA-Approved Psychiatric Medications (2018-2022).CureusPrzegląd badań2024
What Women Want? The State of the Art regarding the Treatment of Young Women with Hypoactive Sexual Desire Disorder.PharmacologyPrzegląd badań2024
Understanding Hypoactive Sexual Desire Disorder (HSDD) in Women: Etiology, Diagnosis, and Treatment.CureusPrzegląd badań2023
Targeting the central melanocortin system for the treatment of metabolic disorders.Nat Rev EndocrinolPrzegląd badań2023
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder.Expert Opin PharmacotherPrzegląd badań2023
Pharmacologic therapeutic options for sexual dysfunction.Curr Opin Obstet GynecolPrzegląd badań2022
Ligands for Melanocortin Receptors: Beyond Melanocyte-Stimulating Hormones and Adrenocorticotropin.BiomoleculesPrzegląd badań2022
Female sexual dysfunctions: an overview on the available therapeutic interventions.Minerva Obstet GynecolPrzegląd badań2022
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women.CNS SpectrPrzegląd badań2022
Management of Hypertension with Female Sexual Dysfunction.Medicina (Kaunas)Przegląd badań2022
Medical Treatment of Female Sexual Dysfunction.Urol Clin North AmPrzegląd badań2022
Pharmacotherapy for Sexual Dysfunction in Women.Curr Psychiatry RepPrzegląd badań2022
Bremelanotide for Treatment of Female Hypoactive Sexual Desire.Neurol IntPrzegląd badań2022
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent.Drug Ther BullPrzegląd badań2021
Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment.J Midwifery Womens HealthPrzegląd badań2021
Management of hypoactive sexual desire disorder in transgender women: a guide for clinicians.Int J Impot ResPrzegląd badań2020
Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder.Ann PharmacotherPrzegląd badań2020
2019 FDA TIDES (Peptides and Oligonucleotides) Harvest.Pharmaceuticals (Basel)Przegląd badań2020
Bremelanotide: First Approval.DrugsPrzegląd badań2019
Bremelanotide (Vyleesi) for hypoactive sexual desire disorder.Med Lett Drugs TherPrzegląd badań2019
Expert opinion on existing and developing drugs to treat female sexual dysfunction.Expert Opin Emerg DrugsPrzegląd badań2018
Effect Size in Efficacy Trials of Women With Decreased Sexual Desire.Sex Med RevPrzegląd badań2018
Evaluation and Management of Hypoactive Sexual Desire Disorder.Sex MedPrzegląd badań2018
Understanding the Role of Serotonin in Female Hypoactive Sexual Desire Disorder and Treatment Options.J Sex MedPrzegląd badań2017
Recent Developments in Psychopharmaceutical Approaches to Treating Female Sexual Interest and Arousal Disorder.Curr Sex Health RepPrzegląd badań2017
Flibanserin for hypoactive sexual desire disorder: place in therapy.Ther Adv Chronic DisPrzegląd badań2017
The Female Sexual Response: Current Models, Neurobiological Underpinnings and Agents Currently Approved or Under Investigation for the Treatment of Hypoactive Sexual Desire Disorder.CNS DrugsPrzegląd badań2015
Drugs in early clinical development for the treatment of female sexual dysfunction.Expert Opin Investig DrugsPrzegląd badań2015
Melanocortin receptor agonists in the treatment of male and female sexual dysfunctions: results from basic research and clinical studies.Expert Opin Investig DrugsPrzegląd badań2014
Central nervous system agents and erectile dysfunction.Urol Clin North AmPrzegląd badań2011
Clinical applications of centrally acting agents in male sexual dysfunction.Int J Impot ResPrzegląd badań2008
Preclinical effects of melanocortins in male sexual dysfunction.Int J Impot ResPrzegląd badań2008
Central nervous system-acting agents and the treatment of erectile and sexual dysfunction.Curr Urol RepPrzegląd badań2007
Clinical application of CNS-acting agents in FSD.J Sex MedPrzegląd badań2007
Melanocortins in the treatment of male and female sexual dysfunction.Curr Top Med ChemPrzegląd badań2007
Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.PeptidesPrzegląd badań2006
PT-141 Palatin.Curr Opin Investig DrugsPrzegląd badań2004
A biodegradable suction patch for sustainable transbuccal peptide delivery.J Control ReleaseNa zwierzętach2025
Female Syrian hamster analyses of bremelanotide, a US FDA approved drug for the treatment of female hypoactive sexual desire disorder.NeuropharmacologyNa zwierzętach2025
Ultra-sensitive quantification of the therapeutic cyclic peptide bremelanotide utilizing UHPLC-MS/MS for evaluation of its oral plasma pharmacokinetics.J Pharm Biomed AnalNa zwierzętach2020
Pharmacological profiling of neuropeptides on rabbit vaginal wall and vaginal artery smooth muscle in vitro.Br J PharmacolNa zwierzętach2008
Bremelanotide: an overview of preclinical CNS effects on female sexual function.J Sex MedNa zwierzętach2007
Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist.Proc Natl Acad Sci U S ANa zwierzętach2004
Salmonellae in gulls and other free-living birds in the Czech Republic.Cent Eur J Public HealthNa zwierzętach1995
Comprehensive characterization of bremelanotide acetate and its degradants by LC-HRMS/MS and predicting epimerization through computational modelling.Anal MethodsInna praca2026
Goldilocks-Inspired Design of Mid-Size Macrocycles for Selective Targeting of Human Melanocortin Receptors.J Med ChemInna praca2026
Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men?J Clin PsychopharmacolInna praca2026
FDA-approved drugs as potential covalent inhibitors of key SARS-CoV-2 proteins: an in silico approach.Turk J BiolInna praca2025
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression.Anticancer ResInna praca2024
Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide: A Randomized, Double-Blind, Placebo Controlled Study.J UrolInna praca2023
Pharmacotherapy for female sexual dysfunctions (FSDs): what is on the market and where is this field heading?Expert Opin PharmacotherInna praca2023
Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials.Diabetes Obes MetabInna praca2022
Structural insights into ligand recognition and activation of the melanocortin-4 receptor.Cell ResInna praca2021
Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".J Sex ResInna praca2021
Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm.J Patient Rep OutcomesInna praca2021
Reliability and validity of the elements of desire questionnaire in premenopausal women with hypoactive sexual desire disorder.J Patient Rep OutcomesInna praca2020
Female Hypoactive Sexual Desire Disorder: A Practical Guide to Causes, Clinical Diagnosis, and Treatment.J Womens Health (Larchmt)Inna praca2020
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.Obstet GynecolInna praca2019
What are the challenges in prescribing pharmacotherapy for female sexual dysfunctions?Expert Opin PharmacotherInna praca2019
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2008
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2008
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2007
Melanocortin receptors, melanotropic peptides and penile erection.Curr Top Med ChemInna praca2007
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2006
Bremelanotide: the female Viagra?Expert Rev Endocrinol MetabInna praca2006
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2005
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2005
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2005
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2004
Gateways to clinical trials.Methods Find Exp Clin PharmacolInna praca2004
[Therapy of erectile dysfunction in 2005].Urologe AInna praca2003

Te prace znaleźliśmy automatycznie w bazie PubMed. Redakcja jeszcze ich nie przeczytała i nie wpływają na żadną ocenę. Tytuły są w oryginale. W każdej grupie pokazujemy najnowsze prace do ustalonego limitu. Pełną listę ma PubMed.

Otwórz w PubMed

Zarejestrowane badania na ludziach (10)

BadaniaEtapStatusLiczba uczestnikówAktualizacja
Single Dose of Vyleesi in Lactating Female Subjects to Measure the Concentration of Bremelanotide in Breast MilkEtap 4Zakończone102026-01-13
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of ObesityEtap 2Trwa, bez nowych osób1082025-03-06
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)Etap 3Zakończone1932024-11-13
A Phase IIb, Multicenter, Open-Label, Prospective Study of Bremelanotide in Diabetic Kidney DiseaseEtap 2Zakończone162024-10-17
Role of the Melanocortin-4 Receptor in Hypoactive Sexual Desire DisorderEtap 4Zakończone402024-08-09
Study to Evaluate Rate of Nausea in Healthy Premenopausal Female Subjects Treated With Single Dose of Bremelanotide Alone or With ZofranEtap 1Zakończone2282022-04-04
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderEtap 3Zakończone7232021-04-09
2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire DisorderEtap 3Zakończone7142021-01-28
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire DisorderEtap 2Zakończone6122014-12-18
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)Etap 2Zakończone–2011-02-23